Market Cap 390.15B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 23.28
Forward PE 15.26
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 6,953,116
Avg Vol 5,995,420
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 29%
Beta 0.36
Analysts Strong Sell
Price Target $245.44

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Wstb20
Wstb20 Jan. 15 at 9:22 PM
$ABBV back to 171.
1 · Reply
Guntz
Guntz Jan. 15 at 8:15 PM
$ABBV All that hard work to claw back wiped out in 15 mins
0 · Reply
Sareptaking
Sareptaking Jan. 15 at 5:26 PM
$IRWD valuation doesn’t make sense. Why doesn’t $ABBV just gobble this up already
2 · Reply
Itzx3ro
Itzx3ro Jan. 15 at 4:47 PM
$ABBV dumping will continue until ex-div date passes. Good buying opportunity tomorrow
0 · Reply
mj_ryder
mj_ryder Jan. 15 at 4:40 PM
$ABBV Holding previous 2 days low. Reclaim VWAP it can easily get back to 220+ by next week, if volume supports and as long as 215 hold. $IWM $SPY
0 · Reply
xtremdelt8
xtremdelt8 Jan. 15 at 4:01 PM
$ABBV Dumping this the day before ex date is wild to me.
0 · Reply
HydrogenH2
HydrogenH2 Jan. 15 at 3:46 PM
$ABBV Next stop under 200 DMA ?? And if it does... next is on the left side of this graph... !!
0 · Reply
scottybebs
scottybebs Jan. 15 at 3:43 PM
$ABBV way too low
0 · Reply
V9RDPUMA
V9RDPUMA Jan. 15 at 3:39 PM
$ABBV WTF now???!!
0 · Reply
Guntz
Guntz Jan. 15 at 3:30 PM
$ABBV The good ole rotation back into tech.
0 · Reply
Latest News on ABBV
AbbVie plans to build out its presence in obesity market

Jan 14, 2026, 2:01 PM EST - 1 day ago

AbbVie plans to build out its presence in obesity market


Abbvie, US reach agreement to cut drug prices

Jan 12, 2026, 6:57 PM EST - 3 days ago

Abbvie, US reach agreement to cut drug prices


AbbVie, RemeGen partner on experimental solid tumor treatment

Jan 12, 2026, 7:39 AM EST - 3 days ago

AbbVie, RemeGen partner on experimental solid tumor treatment


Dividend Income: Lanny's November 2025 Summary

Jan 12, 2026, 5:12 AM EST - 3 days ago

Dividend Income: Lanny's November 2025 Summary

AFL CAT COF CVS CZNC EMR ETN


AbbVie: The Dividend Does Not Lie

Jan 8, 2026, 12:07 PM EST - 7 days ago

AbbVie: The Dividend Does Not Lie


AbbVie Near Deal for Revolution Medicines

Jan 7, 2026, 2:48 PM EST - 8 days ago

AbbVie Near Deal for Revolution Medicines

RVMD


What Can Trigger A Breakout In Abbvie Stock?

Jan 6, 2026, 11:43 AM EST - 9 days ago

What Can Trigger A Breakout In Abbvie Stock?


AbbVie: Rocky Near-Term, Positive Long-Term

Jan 4, 2026, 9:04 AM EST - 11 days ago

AbbVie: Rocky Near-Term, Positive Long-Term


Best Dividend Aristocrats For January 2026

Dec 31, 2025, 8:47 AM EST - 15 days ago

Best Dividend Aristocrats For January 2026

ABT ADM ADP AFL ALB AMCR AOS


Best Dividend Kings: December 2025

Dec 28, 2025, 6:44 AM EST - 18 days ago

Best Dividend Kings: December 2025

ABM ABT ADM ADP AWR BDX BKH


Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 27 days ago

Trump to announce new drug-pricing deals later today

AMGN AZN BMY GILD LLY MRK NVO


AbbVie: Unique Mix Of Growth And Value

Dec 10, 2025, 8:01 PM EST - 5 weeks ago

AbbVie: Unique Mix Of Growth And Value


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 6 weeks ago

Best Dividend Aristocrats For December 2025

ABT ADM ADP AFL ALB AMCR AOS


AbbVie Shares Rise To Intraday High After Key Trading Signal

Nov 12, 2025, 3:06 PM EST - 2 months ago

AbbVie Shares Rise To Intraday High After Key Trading Signal


AbbVie Has Many Bullish Attributes (Technical Analysis)

Nov 11, 2025, 10:40 PM EST - 2 months ago

AbbVie Has Many Bullish Attributes (Technical Analysis)


Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 2 months ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

PFE


Wstb20
Wstb20 Jan. 15 at 9:22 PM
$ABBV back to 171.
1 · Reply
Guntz
Guntz Jan. 15 at 8:15 PM
$ABBV All that hard work to claw back wiped out in 15 mins
0 · Reply
Sareptaking
Sareptaking Jan. 15 at 5:26 PM
$IRWD valuation doesn’t make sense. Why doesn’t $ABBV just gobble this up already
2 · Reply
Itzx3ro
Itzx3ro Jan. 15 at 4:47 PM
$ABBV dumping will continue until ex-div date passes. Good buying opportunity tomorrow
0 · Reply
mj_ryder
mj_ryder Jan. 15 at 4:40 PM
$ABBV Holding previous 2 days low. Reclaim VWAP it can easily get back to 220+ by next week, if volume supports and as long as 215 hold. $IWM $SPY
0 · Reply
xtremdelt8
xtremdelt8 Jan. 15 at 4:01 PM
$ABBV Dumping this the day before ex date is wild to me.
0 · Reply
HydrogenH2
HydrogenH2 Jan. 15 at 3:46 PM
$ABBV Next stop under 200 DMA ?? And if it does... next is on the left side of this graph... !!
0 · Reply
scottybebs
scottybebs Jan. 15 at 3:43 PM
$ABBV way too low
0 · Reply
V9RDPUMA
V9RDPUMA Jan. 15 at 3:39 PM
$ABBV WTF now???!!
0 · Reply
Guntz
Guntz Jan. 15 at 3:30 PM
$ABBV The good ole rotation back into tech.
0 · Reply
BrownDwarf
BrownDwarf Jan. 15 at 3:30 PM
$ABBV why is this dumping???
0 · Reply
JanaJaha
JanaJaha Jan. 15 at 3:29 PM
$ABBV if you buy stock today will you get dividend ?
1 · Reply
taxplanr
taxplanr Jan. 15 at 3:18 PM
$ABBV nice dividend for 110 stock
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 15 at 3:31 AM
Enter: $ABBV Calls Strike Price: $225 Expiry Date: FEB 06 2026 Buy in Price: $3.40 - $4.30 Sell Price: $5.24 Profit : +54% (Turn every $1 into $1.54) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
mikesterz7
mikesterz7 Jan. 15 at 3:08 AM
$ABBV AbbVie already has a long acting amylin analog for the treatment of obesity in its pipeline.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 1:44 AM
$SLS Gps + Keytruda P1/2 MOS of 18.4 Months is Better than a Drug $ABBV bought for $10.1B.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 15 at 1:34 AM
$SLS Another Phase 3 Failure in the Advanced Ovarian Cancer Space "the median OS was 14.2 months (95% CI, 13.0-16.1) vs 13.0 months (95% CI, 11.9-15.1) in each respective arm" https://www.cancernetwork.com/view/atezolizumab-combo-does-not-significantly-boost-survival-in-ovarian-cancer - $IMGN 's Elahere achieved a 16.46 Month MOS and was bought by $ABBV for 10.1B. - GPS + Keytruda $MRK achieved a Phase 2 MOS of 18.4 Months in this same Setting. Now that the AML P3 is completely deRisked and everyone knows GPS is getting FDA Approval for AML Remission Maintenance - MRK - May be willing to Pay the $40B SLS' CEO wants - they already Know GPs +Keytruda will Open 20+ WT1+ Cancer Settings.
0 · Reply
StocktwitsNews
StocktwitsNews Jan. 14 at 11:44 PM
AbbVie Seeks To Grow Obesity Drug Portfolio — Retail Touts Drugmaker As Big Competition To Lilly $ABBV $LLY $NVO https://stocktwits.com/news/equity/markets/abbvie-seeks-to-grow-obesity-drug-portfolio/cmULMtmR477
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 14 at 10:37 PM
$SLS As an FYI for the Passersby, Gps Phase 3 MOS is 100% for Sure Longer than the Statistically Significant 21 month result. - and Aza+VEN the BAT for Control ARM patients is Toxic as F and Recently FAILED 3 Large Phase 3 AML Trials VIALE-T Failed, VERONA Failed, VIALE-M Failed - M for First Remission Maintenance - Aza+Ven also Failed the SLS Phase 3 CONTROL ARM Patients. https://www.reddit.com/r/sellasLifescience/comments/1q6izvc/if_you_are_interested_in_knowing_gps_phase_3/?share_id=yj9ty6n4B_kfvV4Sp1y-c&utm_content=4&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1 if you don’t know Gps is the reason we are seeing near miraculous survival in ALL POOLED SLS P3 patients, you need to do to more DD. - Many Players Paying attention, esp $ABBV $BMY $RHHBY absolutely Know Gps is Getting FDA Approval, and SLS is worth closer to $40B than the current manipulated .67b.
1 · Reply
Stockman824
Stockman824 Jan. 14 at 8:15 PM
$ABBV $BMY $LLY $NVO $VKTX Bidding war between NVO ABBV and AMZN for a HUGE Partnership
0 · Reply
biolover
biolover Jan. 14 at 8:09 PM
If $NVO team looked at this post sep 2024 they could have spared a lot of $400 B MC decline. Now it is not just how much $VKTX BL asks for, It is competing with hard headed managements from $ABBV and $BMY ( and may be others ) But prior to @maziardoustdar scientific team was trashing GIP ( till recently ). Hopefully some lessons learned. $LLY will not take the sector single-handedly
0 · Reply
sirspanky
sirspanky Jan. 14 at 8:03 PM
$IRWD 🚨 WATCH THE 3:30 PM SPIKE. SHORTS ARE TRAPPED. 🚨 Bears tried to use the $ABBV JPM presentation as a "sell the news" event to push us to $4.45. Too bad the "smart money" is already buying the dip. 📉 The Setup: * Strike Zone: $4.00 and $4.50 Calls are deep in-the-money. Market makers ARE BUYING. The Trap: 7.3M shares short with 0 shares available to borrow at some brokers. 📈 The Examples: * Remember $APLD last week? Dropped 4% intraday, spiked EOD, and finished at $38+. Remember $SOUN in August? EOD recovery was the signal for a 20% Friday moonshot. If $IRWD closes green or near $4.65, the Friday Gamma Squeeze is a mathematical certainty. Don’t get shaken out of a Zacks #1 Strong Buy. 💎🙌 $ABBV $APLD $SOUN #ShortSqueeze #GammaSqueeze #JPM2026 #LINZESS
0 · Reply